greeksoup/ stock research
Stock research / United States / TARS / Filings

Tarsus Pharmaceuticals, Inc. SEC filings

Tarsus Pharmaceuticals filed 23 documents with the SEC in the last twelve months, the latest report being the 10-Q of 6 August 2026. The latest filing, on 13 October 2026, was an 8-K/A: 8-k/a.

Filings in twelve months2313 of them 8-K news
Latest report10-Qfiled 6 Aug 2026
Latest filing8-K/A13 Oct 2026
Last results, two-day move+5.7%results filed 6 Aug 2026
New to this? How to read this page
  1. Companies file with the SEC when something happens. 10-Q and 10-K are the quarterly and annual reports; 8-K is news that cannot wait for the next report.
  2. An 8-K says which items it covers, such as results, a change at the top or a big contract. A foreign company files a 6-K instead.
  3. The results release is usually an 8-K filed the day results come out, before the 10-Q or 10-K.
  4. Every filing links to the original on EDGAR, the SEC's own site.

Twelve months of filings

by kind

Most of the filings were other company news (9). Results came out 4 times.

Each mark is one filing on the day it was filed, in rows by kind. Hover or tap a mark for the form and what it was about.

The share price around each results release

close before to close after

Over the last 4 releases the share price moved 5.6% on average in the two days around results, the most on 23 Feb 2026 (+12.6%).

4 Nov 2025-2.3%$69.79 to $68.20
23 Feb 2026+12.6%$66.61 to $75.01
6 May 2026-1.7%$65.04 to $63.96
6 Aug 2026+5.7%$61.29 to $64.79
Daily closeResults filed

Each ring marks a results filing. The move runs from the last close before the filing to the first close after it, so it covers results released before the open or after the close. Hover the line for any day's close.

What the company told investors on 8-K

13 filings

Tarsus Pharmaceuticals's 13 news filings (8-K) were mostly about other events (4) and results of operations (4).

  • Other eventsNews the company chose to file
    4 · latest 10 Sep 2026
  • Results of operationsThe quarterly results release
    4 · latest 6 Aug 2026
  • Material agreementA large contract or deal was signed
    3 · latest 6 Aug 2026
  • Unregistered sale of equityShares sold privately
    3 · latest 6 Aug 2026
  • Officer or director changeSomeone joined, left or changed role at the top
    2 · latest 13 Jul 2026
  • Amended current reportA correction or update to an earlier 8-K
    1 · latest 13 Oct 2026
  • Acquisition or disposition completedA purchase or sale of a business closed
    1 · latest 10 Sep 2026
  • Shareholder voteResults of a vote at a shareholder meeting
    1 · latest 29 Jun 2026
  • Regulation FD disclosureMaterial shared with investors, often slides or a presentation
    1 · latest 12 Jan 2026

Each line is one kind of news, with what it means in plain words. Each square is one filing; a filing can carry more than one kind, so the squares can add up to more than the filings. The date opens the latest one on EDGAR.

How it compares

every company on the site

    The bar ranks every company on the site from the lowest on the left to the highest on the right, in three equal thirds; the small figures under it are the values where each third starts, and the black tick is the middle company. The orange dot is this company; the grey ticks are the other companies in its industry (hover or tap for names). A hatched block is companies tied at none.

    Every filing as a table

    In the last twelve months Tarsus Pharmaceuticals, Inc. filed 23 documents with the SEC of the kinds listed here: 13 current reports (8-K), about 4 other events; 4 results of operations; 3 material agreement; 3 unregistered sale of equity; 2 officer or director change; 3 quarterly reports (10-Q), 2 shelf registrations (S-3ASR), 1 annual report to shareholders (ARS), 1 additional proxy material (DEFA14A), 1 proxy statement (DEF 14A), 1 employee share plan registration (S-8). The latest, filed 13 October 2026: 8-K/A, amended current report. The 10-K, the 10-Qs and the proxy statement themselves, each with a link to open it, are on the documents page.

    FiledFormWhat it was aboutPeriod or event dateFiling
    13 October 20268-K/Aamended current report4 September 2026EDGAR
    13 October 2026S-3ASRshelf registrationEDGAR
    13 October 2026S-3ASRshelf registrationEDGAR
    10 September 20268-KAcquisition or disposition completed, Other events4 September 2026EDGAR
    6 August 202610-Qquarterly report30 June 2026EDGAR
    6 August 20268-KResults of operations6 August 2026EDGAR
    6 August 20268-KMaterial agreement, Unregistered sale of equity, Other events5 August 2026EDGAR
    6 August 20268-KMaterial agreement, Unregistered sale of equity, Other events31 July 2026EDGAR
    13 July 20268-KOfficer or director change13 July 2026EDGAR
    8 July 20268-KMaterial agreement, Unregistered sale of equity, Other events6 July 2026EDGAR
    29 June 20268-KShareholder vote25 June 2026EDGAR
    6 May 202610-Qquarterly report31 March 2026EDGAR
    6 May 20268-KResults of operations6 May 2026EDGAR
    28 April 2026ARSannual report to shareholders31 December 2025EDGAR
    28 April 2026DEFA14Aadditional proxy materialEDGAR
    28 April 2026DEF 14Aproxy statement25 June 2026EDGAR
    23 February 2026S-8employee share plan registrationEDGAR
    23 February 202610-Kannual report31 December 2025EDGAR
    23 February 20268-KResults of operations23 February 2026EDGAR
    18 February 20268-KOfficer or director change18 February 2026EDGAR
    12 January 20268-KRegulation FD disclosure12 January 2026EDGAR
    4 November 202510-Qquarterly report30 September 2025EDGAR
    4 November 20258-KResults of operations4 November 2025EDGAR
    An 8-K is what a company files within four business days of a material event; the SEC numbers the events, and the words here are the SEC's own headings, shortened.
    Read moreForm 4, Form 144, 13F and Schedule 13D and 13G have their own pages. Prospectus supplements and correspondence are not listed.